SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    World Health Organization. http://www.who.int/research/en. Accessed July 2012.
  • 2
    Sturm R. Increases in clinically severe obesity in the United States, 1986–2000. Arch Intern Med 2003; 163: 2146-2148.
  • 3
    Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-117.
  • 4
    Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285.
  • 5
    Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, Chayama K, Saibara T, JSG-NAFLD. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 2012; 47: 586-595.
  • 6
    Fassio E, Alvarez E, Domínguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004; 40: 820-826.
  • 7
    Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141: 1249-1253.
  • 8
    Bhagat V, Mindikoglu AL, Nudo CG, Schiff ER, Tzakis A, Regev A. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl 2009; 15: 1814-1820.
  • 9
    Malik SM, deVera ME, Fontes P, Shaikh O, Ahmad J. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant 2009; 9: 782-793.
  • 10
    Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl 2010; 16: 431-439.
  • 11
    Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215-1219.
  • 12
    Bowlus CL, Willner I, Zern MA, Reuben A, Chen P, Holladay B, et al. Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiency. Clin Gastroenterol Hepatol 2005; 3: 390-396.
  • 13
    Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, Powell EE. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55: 529-535.
  • 14
    Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-644.
  • 15
    Chiang CH, Yang HI, Jen CL, Lu SN, Wang LY, You SL, et al. Association between obesity, hypertriglyceridemia and low hepatitis B viral load. Int J Obes (Lond); doi:10.1038/ijo.2012.63.
  • 16
    Lesmana LA, Lesmana CR, Pakasi LS, Krisnuhoni E. Prevalence of hepatic steatosis in chronic hepatitis B patients and its association with disease severity. Acta Med Indones 2012; 44: 35-39.
  • 17
    Ruhl CE, Everhart JE. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol 2005; 3: 1260-1268.
  • 18
    Berzigotti A, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Morillas R, et al.; for Portal Hypertension Collaborative Group. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology 2011; 54: 555-561.
  • 19
    Chen Y, Wang X, Wang J, Yan Z, Luo J. Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. Eur J Cancer; doi:10.1016/j.ejca.2012.02.063.
  • 20
    Pekow JR, Bhan AK, Zheng H, Chung RT. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 2007; 109: 2490-2496.
  • 21
    Harinstein ME, Flaherty JD, Ansari AH, Robin J, Davidson CJ, Rossi JS, et al. Predictive value of dobutamine stress echocardiography for coronary artery disease detection in liver transplant candidates. Am J Transplant 2008; 8: 1523-1528.
  • 22
    Møller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002; 87: 9-15.
  • 23
    Patel S, Kiefer TL, Ahmed A, Ali ZA, Tremmel JA, Lee DP, et al. Comparison of the frequency of coronary artery disease in alcohol-related versus non-alcohol-related endstage liver disease. Am J Cardiol 2011; 108: 1552-1555.
  • 24
    McAvoy NC, Kochar N, McKillop G, Newby DE, Hayes PC. Prevalence of coronary artery calcification in patients undergoing assessment for orthotopic liver transplantation. Liver Transpl 2008; 14: 1725-1731.
  • 25
    Bianchi G, Nicolino F, Passerini G, Grazi GL, Zappoli P, Graziani R, et al. Plasma total homocysteine and cardiovascular risk in patients submitted to liver transplantation. Liver Transpl 2006; 12: 105-111.
  • 26
    Coss E, Watt KD, Pedersen R, Dierkhising R, Heimbach JK, Charlton MR. Predictors of cardiovascular events after liver transplantation: a role for pretransplant serum troponin levels. Liver Transpl 2011; 17: 23-31.
  • 27
    Wilson PW, Bozeman SR, Burton TM, Hoaglin DC, Ben-Joseph R, Pashos CL. Prediction of first events of coronary heart disease and stroke with consideration of adiposity. Circulation 2008; 118: 124-130.
  • 28
    Vasan RS, Sullivan LM, Wilson PW, Sempos CT, Sundström J, Kannel WB, et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med 2005; 142: 393-402.
  • 29
    Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al.; for INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.
  • 30
    D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 743-753.
  • 31
    Raval Z, Harinstein ME, Skaro AI, Erdogan A, DeWolf AM, Shah SJ, et al. Cardiovascular risk assessment of the liver transplant candidate. J Am Coll Cardiol 2011; 58: 223-231.
  • 32
    McCaughan G. Trekking new ground: overcoming medical and social impediments for extended criteria recipients. Liver Transpl 2012; 18( suppl 2).
  • 33
    Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int 2008; 73: 19-33.
  • 34
    National Cancer Institute. http://www.cancer.gov. Accessed July 2012.
  • 35
    Crawford DH, Shepherd RW, Halliday JW, Cooksley GW, Golding SD, Cheng WS, Powell LW. Body composition in nonalcoholic cirrhosis: the effect of disease etiology and severity on nutritional compartments. Gastroenterology 1994; 106: 1611-1617.
  • 36
    Figueiredo FA, De Mello Perez R, Kondo M. Effect of liver cirrhosis on body composition: evidence of significant depletion even in mild disease. J Gastroenterol Hepatol 2005; 20: 209-216.
  • 37
    Tsiaousi ET, Hatzitolios AI, Trygonis SK, Savopoulos CG. Malnutrition in end stage liver disease: recommendations and nutritional support. J Gastroenterol Hepatol 2008; 23: 527-533.
  • 38
    Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008; 48: 119-128.
  • 39
    Chugh PK, Sharma S. Recent advances in the pathophysiology and pharmacological treatment of obesity. J Clin Pharm Ther; doi:10.1111/j.1365–2710.2012.01347.x.
  • 40
    Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al.; for NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685.
  • 41
    Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306: 1549-1556.
  • 42
    Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482: 179-185.
  • 43
    Watt KD, Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol 2010; 53: 199-206.
  • 44
    American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2009; 32: S13-S61.
  • 45
    Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009; 137: 532-540.
  • 46
    Kral JG, Thung SN, Biron S, Hould FS, Lebel S, Marceau S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004; 135: 48-58.
  • 47
    Mosko JD, Nguyen GC. Increased perioperative mortality following bariatric surgery among patients with cirrhosis. Clin Gastroenterol Hepatol 2011; 9: 897-901.
  • 48
    Takata MC, Campos GM, Ciovica R, Rabl C, Rogers SJ, Cello JP, et al. Laparoscopic bariatric surgery improves candidacy in morbidly obese patients awaiting transplantation. Surg Obes Relat Dis 2008; 4: 159-164.
  • 49
    Campsen J, Zimmerman M, Shoen J, Wachs M, Bak T, Mandell MS, Kam I. Adjustable gastric banding in a morbidly obese patient during liver transplantation. Obes Surg 2008; 18: 1625-1627.
  • 50
    Heimbach J, Swain J, Poterucha J, Charlton M, Rosen C, DiCecco S, Fransicso-Zeller N, Watt K. Combined liver transplant plus sleeve gastrectomy for pretransplant patients with refractory obesity. Hepatology 2011;644A [abstract #582].
  • 51
    Dick AA, Spitzer AL, Seifert CF, Deckert A, Carithers RL Jr, Reyes JD, Perkins JD. Liver transplantation at the extremes of the body mass index. Liver Transpl 2009; 15: 968-977.
  • 52
    Leonard J, Heimbach JK, Malinchoc M, Watt K, Charlton M. The impact of obesity on long-term outcomes in liver transplant recipients—results of the NIDDK liver transplant database. Am J Transplant 2008; 8: 667-672.
  • 53
    Nair S, Vanatta JM, Arteh J, Eason JD. Effects of obesity, diabetes, and prior abdominal surgery on resource utilization in liver transplantation: a single-center study. Liver Transpl 2009; 15: 1519-1524.
  • 54
    Dick AA, Perkins JD, Spitzer AL, Lao OB, Healey PJ, Reyes JD. Impact of obesity on children undergoing liver transplantation. Liver Transpl 2010; 16: 1296-1302.
  • 55
    Morris K, Tuorto S, Gönen M, Schwartz L, DeMatteo R, D'Angelica M, et al. Simple measurement of intra-abdominal fat for abdominal surgery outcome prediction. Arch Surg 2010; 145: 1069-1073.
  • 56
    van Vledder MG, Levolger S, Ayez N, Verhoef C, Tran TC, Ijzermans JN. Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg 2012; 99: 550-557.
  • 57
    Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008; 9: 629-635.
  • 58
    Englesbe MJ, Patel SP, He K, Lynch RJ, Schaubel DE, Harbaugh C, et al. Sarcopenia and mortality after liver transplantation. J Am Coll Surg 2010; 211: 271-278.
  • 59
    Richards J, Gunson B, Johnson J, Neuberger J. Weight gain and obesity after liver transplantation. Transpl Int 2005; 18: 461-466.
  • 60
    Wawrzynowicz-Syczewska M, Karpińska E, Jurczyk K, Laurans L, Boroń-Kaczmarska A. Risk factors and dynamics of weight gain in patients after liver transplantation. Ann Transplant 2009; 14: 45-50.
  • 61
    Sauers L. Incidence, progression and predictors of metabolic syndrome and cardiovascular outcomes before and after liver transplantation Hepatology 2011;412 A [abstract 109].
  • 62
    Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010; 10: 1420-1427.